Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging
- PMID: 21998047
- DOI: 10.1148/radiol.11101840
Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging
Abstract
Purpose: To describe imaging findings of early hepatocellular carcinoma (HCC) at gadoxetic acid-enhanced magnetic resonance (MR) imaging, dynamic contrast material-enhanced computed tomography (CT), CT during arterial portography (CTAP), and CT during hepatic arteriography (CTHA) and to compare the diagnostic performance of each modality for small (≤ 2 cm) HCC.
Materials and methods: The institute ethics committee deemed study approval unnecessary. One hundred eight resected small lesions in 64 patients were diagnosed as a dysplastic nodule (DN) (n = 12), progressed HCC (n = 66), or early HCC (n = 30). All but two patients underwent all imaging examinations. The imaging characteristics of the lesions with each modality were determined. To evaluate the diagnostic performance of the modalities, two radiologists graded the presence of HCC with use of a five-point confidence scale. The area under the receiver operating characteristic curve (A(z)), sensitivity, and specificity of each modality were compared.
Results: The imaging features that are statistically significant for differentiating an early HCC from a DN include fat-containing lesions at dual-echo T1-weighted MR imaging (seen in 16 of the 30 early HCCs and none of the DNs), low attenuation at unenhanced CT (seen in 13 of the 30 early HCCs and none of the DNs), low attenuation at CTAP (seen in 11 of the 30 early HCCs and none of the DNs), and low signal intensity at hepatocyte phase gadoxetic acid-enhanced MR imaging (seen in 29 of the 30 early HCCs and none of the DNs). The diagnostic performance of gadoxetic acid-enhanced MR imaging (A(z), 0.98 and 0.99) was significantly greater than that of contrast-enhanced CT (A(z), 0.87) and CTHA-CTAP (A(z), 0.85 and 0.86) owing to its significantly higher sensitivity (P < .001).
Conclusion: Gadoxetic acid-enhanced MR imaging is the most useful imaging technique for evaluating small HCC, including early HCC.
© RSNA, 2011.
Similar articles
-
Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging.Radiology. 2010 Jul;256(1):151-8. doi: 10.1148/radiol.10091885. Radiology. 2010. PMID: 20574092
-
Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging.Radiology. 2014 Jun;271(3):748-60. doi: 10.1148/radiol.14131996. Epub 2014 Feb 1. Radiology. 2014. PMID: 24588677
-
Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.Invest Radiol. 2010 Feb;45(2):96-103. doi: 10.1097/RLI.0b013e3181c5faf7. Invest Radiol. 2010. PMID: 20057319
-
Imaging of early hepatocellular carcinoma and adenomatous hyperplasia (dysplastic nodules) with dynamic ct and a combination of CT and angiography: experience with resected liver specimens.Intervirology. 2004;47(3-5):199-208. doi: 10.1159/000078473. Intervirology. 2004. PMID: 15383730 Review.
-
Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma.J Magn Reson Imaging. 2015 Feb;41(2):251-65. doi: 10.1002/jmri.24712. Epub 2014 Aug 8. J Magn Reson Imaging. 2015. PMID: 25104398 Review.
Cited by
-
Quantitative assessment of HCC wash-out on CT is a predictor of early complete response to TACE.Eur Radiol. 2021 Sep;31(9):6578-6588. doi: 10.1007/s00330-021-07792-2. Epub 2021 Mar 18. Eur Radiol. 2021. PMID: 33738601 Free PMC article.
-
Comparison of values of CT and MRI imaging in the diagnosis of hepatocellular carcinoma and analysis of prognostic factors.Oncol Lett. 2019 Jan;17(1):1184-1188. doi: 10.3892/ol.2018.9690. Epub 2018 Nov 12. Oncol Lett. 2019. PMID: 30655882 Free PMC article.
-
Hepatocellular Carcinoma: State of the Art Imaging and Recent Advances.J Clin Transl Hepatol. 2019 Mar 28;7(1):72-85. doi: 10.14218/JCTH.2018.00032. Epub 2019 Feb 17. J Clin Transl Hepatol. 2019. PMID: 30944823 Free PMC article. Review.
-
Hepatocellular Carcinoma: Current Imaging Modalities for Diagnosis and Prognosis.Dig Dis Sci. 2019 Apr;64(4):934-950. doi: 10.1007/s10620-019-05547-0. Dig Dis Sci. 2019. PMID: 30825108 Review.
-
Preoperative gadoxetic Acid-enhanced MRI and simultaneous treatment of early hepatocellular carcinoma prolonged recurrence-free survival of progressed hepatocellular carcinoma patients after hepatic resection.HPB Surg. 2014;2014:641685. doi: 10.1155/2014/641685. Epub 2014 Feb 19. HPB Surg. 2014. PMID: 24701029 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical